Form 4: Pulmonx Corp CEO Steven S. Williamson Reports Stock and Option Grants

Steven S. Williamson, CEO of Pulmonx Corp, reports the acquisition of restricted stock units and stock options.

Summary

• On March 15, 2024, Steven S. Williamson, the President and CEO of Pulmonx Corp, reported changes in his beneficial ownership of the company's securities.
• He acquired 205,286 shares of common stock through a grant of Restricted Stock Units (RSUs) at a price of $0.
• These RSUs vest with 25% vesting on March 3, 2025, and the remainder vesting in equal quarterly installments over the subsequent three-year period.
• Williamson also acquired options to purchase 425,116 shares of common stock at an exercise price of $8.95.
• These options vest with 25% vesting on March 3, 2025, and the remainder vesting in equal monthly installments over the subsequent three-year period.
• Following these transactions, Williamson directly owns 205,286 shares of common stock and options to purchase 425,116 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grants align management interests with shareholders, but there's no immediate impact on the company's financials.

Positives

• The grant of RSUs and stock options to the CEO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CEO.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of executive compensation in the biotechnology and medical device industries.
• Vesting schedules are typically structured to incentivize long-term performance and retention, often spanning three to four years.
• The specific number of shares and option grants are relative to the size and stage of the company, as well as the executive's role and responsibilities.

Stakeholder Impact

• The grants align the CEO's interests with shareholders, potentially leading to increased focus on long-term value creation.

Key Dates